OBJECTIVES: Genetic defects associated with bicuspid aortopathy have been infrequently analysed. Our goal was to examine the prevalence of rare genetic variants in patients with a bicuspid aortic valve (BAV) with a root phenotype using next-generation sequencing technology.
INTRODUCTION
Phenotypic heterogeneity in bicuspid aortic valve (BAV) disease has been increasingly recognized during the last decade [1, 2] . Flow-related parameters and genetic factors have been claimed to explain the phenomenon of bicuspid aortopathy [3] . Recent efforts have focused on the identification of predictive parameters of aortopathy to provide a prognostic classification model and the best tailored approach for such patients [4] .
The BAV root phenotype has been reported as an uncommon form of BAV disease (i.e. 10-15% of the BAV population), found predominantly in young men with BAV and characterized by dilatation of the sinus of Valsalva and aortic regurgitation [5] . This BAV cohort is dissimilar from the 'BAV stenosis' phenotype, which is assumed to be a predominantly haemodynamic sequela and is associated with dilatation of the supracoronary ascending aorta [6] . Although the BAV root phenotype is supposed to be a congenital Marfan-like disorder, genetic defects have not been systematically analysed [7] . Therefore, our goal was to assess the prevalence of genetic defects in patients with BAV root phenotype using next-generation sequencing (NGS) technology.
METHODS
We identified a total of 124 patients with BAV who underwent aortic valve ± proximal aortic surgery for BAV insufficiency and aortic root dilation (i.e. diameter of the sinus of Valsalva larger than that of the tubular ascending aorta) during a 20-year period from the institutional BAV database (n = 812) at the Central Hospital, Bad Berka, Germany. Our local ethics committee approved this study, and each patient gave written informed consent.
Only patients with isolated/predominant BAV insufficiency were included. Patients with aortic stenosis (i.e. mean transvalvular gradient > _20 mmHg) were excluded. Moreover, all study patients had an aortic root diameter of >40 mm. Patients with Marfan syndrome and those without dilation of the aortic root were excluded. Moreover, patients with BAV who had their maximal aortic diameter at the level of the tubular ascending aorta were not included. All patients with endocarditis were excluded. These inclusion criteria resulted in 124 consecutive patients with BAV root phenotype (15% of BAV cohort) who were available for longterm follow-up. After exclusion of all patients who died postoperatively (n = 17), were lost during follow-up (n = 15) and who rejected participation (n = 29), we identified a total of 63 patients (mean age 46 ± 10 years, 92% men) who served as our study population.
The primary end-point of the current study was the prevalence of genetic defects in patients with the BAV root phenotype. Secondary end-points were the need for redo aortic surgery, the occurrence of type A dissection, echocardiographic evidence of progressive aortopathy and sudden cardiac death during the follow-up period.
Definitions and measurements
The definition of aortic valve morphology (i.e. BAV vs TAV) was described previously [7] ; the Sievers classification system was used to categorize the bicuspid aortic valves [8] . Aortic regurgitation was quantified using the published echocardiography guidelines [9] . All patients with BAV with a mean transvalvular gradient >20 mmHg and aortic insufficiency were diagnosed as having mixed lesions and were excluded.
Proximal aortic diameters were determined as described in our previous study [7] . Briefly, the dimensions of the proximal aorta were assessed by multiple echocardiographic measurements in the parasternal long-axis view and by routine aortic angiography. All patients with an aortic root diameter > _40 mm, as diagnosed by these screening examinations, underwent preoperative computed tomography or magnetic resonance imaging (MRI) of the thoracic aorta, and aortic dimensions were measured in accordance with previously published recommendations [10] .
In accordance with the American College of Medical Genetics and Genomics guidelines, our definition of 'unlikely pathogenic' variants resembles that of those 'likely benign' as defined by guidelines. This definition was applied if the variant was present in the unaffected population with an allele frequency inconsistent with the clinical significance, based on the mode of inheritance and severity of the disorder. Variants were considered 'potentially pathogenic' if they did not meet the requirements of other categories and in silico tools predicted different outcomes. Thus 'potentially pathogenic' resembles the American College of Medical Genetics and Genomics category of 'variant of uncertain clinical significance'. The category 'likely pathogenic' was applied if the variant was not present in any publicly available database at an allele frequency consistent with being a benign variant and if this variant was predicted as 'damaging' by most in silico tools. Thus, 'likely pathogenic' is equivalent to the American College of Medical Genetics and Genomics category 'likely pathogenic'.
Study population
Demographics and intraoperative variables are summarized in Table 1 . Our study cohort consisted of young men with BAV insufficiency and aortic root dilatation.
The surgical approach to the aortic root in patients with the BAV root phenotype changed over time. During the period from 1995 to 2010, all patients with BAV insufficiency underwent (B) During the second study period (i.e. 2011-2015), we adopted a systematic approach to repair regurgitant BAVs in our institution. All patients presenting with BAV insufficiency and aortic root dilatation were considered for a modified remodelling procedure, as described by Sch€ afer et al. [11] . A total of 13 (72%) patients with the BAV root phenotype who were included during this study period underwent aortic valve sparing root surgery. The remaining 5 patients with a severely restrictive raphe had a composite graft replacement.
Follow-up
Cross-sectional, telephone-based follow-up revealed 63 (51%) patients who were still alive and willing to participate. Moreover, all patients received a written follow-up questionnaire and were asked to answer specific questions including their family history of BAV/aortopathy. All 63 patients agreed to participate. Followup was scheduled from March to December 2015. Follow-up visits included aortic imaging (transthoracic echocardiography and computed tomography/MRI) as well as peripheral blood sampling for genetic testing (Fig. 1 ).
Genetic analysis
DNA was isolated from peripheral blood samples (1 ml) using a standardized protocol for the MagCoreV R HF16 (Nippon Genetics Europe GmbH, Düren, Germany). NGS libraries were prepared using a custom HaloPlex HS (Agilent Technologies, Santa Clara, CA, USA) gene panel and sequenced on an Illumina MiSeq (Illumina, San Diego, CA, USA) system with a V3 chemistry kit. A total of 20 candidate genes associated with BAV aortopathies were included in the custom panel: ACTA2, AXIN1, ELN, FBN1, FGF8, FN1, GATA5, HOXA1, KCNJ2, MMP9, MYH11, NKX2-5, NOS3, NOTCH1, PDIA2, SMAD6, TGFB1, TGFB2, TGFBR1 and UFD1L. The aortopathy gene panel was designed based on data from the literature reporting genetic abnormalities in patients with BAV aortopathy and included the genes that were reported most consistently. All of the variants reported here were sequenced with a coverage of >200Â (807Â on average) and investigated manually for sequencing artefacts or pseudogenes (Supplementary Material, Table S1 ). Consequently, all the variants reported here were considered genuine, and no further validation with another method was carried out. For data analysis, an in-house NGS pipeline was used. Primary data were filtered with Illumina's real-time analysis software, and the resulting fastq files were aligned to the human genome reference hg19 with the Burrows-Wheeler alignment algorithm. Data enhancement steps were carried out using PICARD v1.112 and GATK v3.3. The UnifiedGenotyper of GATK identified single-nucleotide variants and short indels (i.e. insertion-deletion polymorphisms), which were then annotated using Annovar software (http://annovar. openbioinformatics.org/en/latest/). Subsequently, the identified variants were filtered to include only those listed in the 1000Genome or the ESP6500 database with an allele frequency of <0.01 or those that were not listed at all. Only exonic or splicing variants were kept in the record and additionally filtered for non-synonymous single-nucleotide changes or indels. The pathogenicity of identified genetic variants was assessed using in silico prediction tool analysis (PolyPhen, MutationTaster, SIFT and LRT). These programmes provide a statistical functional assessment of identified rare genetic variants (RGVs) based on the predicted effect on protein structure and stability and the overall conservation of the particular site in comparison with a wild-type genotype. 
Statistics
Standard definitions were used for patient variables and outcomes. Categorical variables are presented as percentages, and continuous variables are expressed as mean ± SD with range throughout the manuscript. Continuous variables between the study subgroups were compared using the unpaired two-sided t-test. Categorical variables were analysed using the v 2 test or the Fisher's exact test, as appropriate. Data were tested for normal distribution using the Kolmogorov-Smirnov test. All statistical analyses were performed with the IBM SPSS 22.0 software (IBM Corp, New York, USA). Proximal aortic dimensions were compared for differences using the unpaired two-tailed t-test. All P values <0.05 were considered statistically significant. 
Based on in silico prediction scores and previous literature reports (i.e. published in combination with congenital syndromes). Table S2 . Potentially or likely pathogenic RGVs have been demonstrated most commonly in the NOTCH1 gene (29%). Our current analysis yielded a low prevalence of FBN1 variants (i.e. 9%). A single patient with an FBN1 variant (i.e. p.T1020A) had no further manifestation of Marfan syndrome, except for an aortic root aneurysm. His family history was negative for congenital connective tissue disorders as well as for BAV morphology.
RESULTS

Genetic analysis
Clinical follow-up
Clinical follow-up data (i.e. 607 patient-years) were available for all patients. The mean post-AVR follow-up was 10.3 ± 4.9 years (range, 0-19 years). Adverse aortic events (i.e. redo aortic surgery, progression of aortic root diameters > _5 mm) were analysed and compared between Groups I and II.
There were no significant differences in baseline characteristics between Group I and Group II (Table 1) . We found only a tendency towards younger age (i.e. 44.5 ± 14 years vs 48.5 ± 9 years, P = 0.2) and a higher prevalence of family history in Group I (i.e. 21% vs 9%, P = 0. NOS3 variant [(c.1263 C > G (p.H421Q) ] in Patient #38. At least two relatives in these families died suddenly or underwent aortic surgery due to aneurysm/aortic dissection. Preoperative aortic root diameters were comparable between the study cohorts (i.e. 46.5 ± 11 mm in Group I vs 48.6 ± 8 mm in Group II, P = 0.3). Similarly, there were no significant differences in surgical strategy between subgroups. We found only a slightly higher prevalence of aortic root replacement (i.e. valve sparing and composite graft) in Group I (i.e. 69% vs 48%, P = 0.07).
Proximal aortic surgery
Redo aortic surgery was performed in 5 patients in Group II (11%). Progressive increase in aortic root diameter was the indication for a redo aortic operation in all 5 patients, who underwent prior isolated AVR. The mean period between AVR and redo aortic surgery was 7 ± 2 years. All 5 patients underwent a composite graft replacement and survived the redo surgery uneventfully.
Progression of aortic root diameter
The progression of aortic root diameter was assessed in the subgroup of 29 (46%) patients with BAV who underwent an operation only for AVR. MRI-based aortic root diameters (i.e. pre-AVR vs post-AVR) were compared between Group I (n = 6) and Group II (n = 23). The mean length of follow-up with an MRI was 11.1 ± 5.5 years (a total of 312 patient-years). The mean diameter of the aortic root increased from 45.0 ± 3.6 mm preoperatively to 46.5 ± 6.3 mm post-AVR in Group I (P = 0.5) compared with 45.7 ± 4.4 mm preoperatively to 47.8 ± 8.1 mm post-AVR in Group II (P = 0.2). The progression rate of maximal aortic root diameter was comparable between study subgroups (i.e. 1.5 ± 0.6 mm in Group I vs 2.9 ± 2.5 mm in Group II, P = 0.5). An MRI-defined progression of aortic root diameter > _5 mm was revealed in 1 (5%) patient in Group I vs 5 (11%) patients in Group II (P = 0.7). All 5 patients in Group II underwent an elective redo aortic operation.
Subgroup with NOTCH1 variants
NOTCH1 variants were the most common genetic variants identified in our study (i.e. 6 distinct RGVs in 5 patients). No clinically relevant differences could be identified between NOTCH1(+) variant and NOTCH1(-) variant subgroups in terms of age at presentation (i.e. 52 ± 11 years vs 47 ± 11 years, P = 0.4), pre-AVR aortic dimensions (i.e. 45 ± 12 mm vs 48 ± 8, P = 0.4) and family history of BAV/aortopathy. Moreover, no relevant differences in the surgical strategy (i.e. prevalence of aortic root replacement) were found. No post-AVR aortic events occurred in these 5 NOTCH1(+) RGV patients during the follow-up period.
DISCUSSION
Haemodynamic effects related to abnormal transvalvular flow patterns and manifestations of primary genetic disorders are thought to interact to various degrees, simultaneously causing the progression of BAV-associated aortopathy [16] . Moreover, BAV is a heterogeneous disease, and the pathogenetic heterogeneity of BAV valvuloaortic phenotypes may potentially explain the variable expression of proximal aortic involvement [1] [2] [3] . Only limited data are available on the pathogenetic background of specific BAV phenotypes. The subgroup of young, predominantly male patients with BAV with dilatation of the aortic root and aortic valve insufficiency (i.e. root phenotype) has been previously reported [5, 7, 17] . This form of BAV aortopathy appears to be clinically different from the aortopathy observed in patients with BAV stenosis and concomitant dilatation of the tubular ascending aorta [5] [6] [7] . Case studies reported genetic abnormalities in BAV root phenotype, and mutations in the TGFBR2, FBN1 and SMAD2 genes have been demonstrated in families with this aortopathy [18] [19] [20] . Biner et al. [21] demonstrated that the proximal aortopathy observed in first-degree relatives of patients with BAV presented with a root aneurysm. Loscalzo et al. [22] reported the association of BAV disease and familial thoracic aortic aneurysms. Rheological patterns and histological lesions in the proximal aortic wall have been shown to be different in patients with BAV insufficiency compared with those with BAV stenosis [23] [24] [25] . Therefore, our goal was to systematically analyse the prevalence of genetic defects in patients with the BAV root phenotype using NGS technology. We hypothesized that the potential to find relevant genetic defects should be highest in this cohort of BAV patients.
The most important finding of our study is the high prevalence of potentially or likely pathogenic variants in patients with the BAV root phenotype. A total of 64 RGVs were found in 38 (61%) patients, whereas only 24 (38%) variants were identified as potentially or likely pathogenic. To the best of our knowledge, this is the first clinical report that found such a high prevalence of potentially deleterious genetic variants in patients with BAV. Previous studies included either very limited numbers of candidate genes [26] or revealed a lower prevalence of genetic abnormalities [27] . In a recent study, Dargis et al. [28] identified 19 potentially pathogenic variants in a BAV cohort. However, most of these variants were not associated with BAV morphology in the case-control comparative analysis. This discrepancy may be explained by the fact that the above-mentioned study did not focus specifically on the BAV root phenotype that is supposed to represent the genetically triggered form of BAV aortopathy.
Our previous retrospective study showed that patients with the BAV root phenotype are prone to life-threatening adverse aortic events after an isolated AVR operation [7] . Nonetheless, in this study, we were unable to demonstrate clinically relevant differences in the severity of the aortopathy between the cohort with (n = 19) and that without (n = 44) genetic abnormalities. Both subgroups had comparable aortic root dimensions at the time of the operation and during the follow-up period. Moreover, there was no difference in the clinical outcome between the subgroup of patients with identified RGVs versus that without such variants. The fact that the presence of rare genetic variants did not translate into worse clinical outcomes in our study has two possible explanations: (i) All patients with the BAV root phenotype have a higher risk of aortic events compared with those presenting with BAV stenosis. Although rare genetic variants were identified in 30% of patients with a root phenotype, we cannot exclude the possibility that all of the remaining patients had such genetic abnormalities in other genes not included in our analysis. (ii) The primary end-point of our study was to evaluate the prevalence of genetic abnormalities in a cohort with the BAV root phenotype, which is hypothesized to put the person at risk for underlying genetic defects. Therefore, our study was not primarily powered to compare the clinical outcome in RGVs(+) vs RGVs(-) cohorts, and sample sizes in both subgroups were limited.
The tendency towards more common aortic root replacement at the time of the first operation in Group I, which resulted in a lower rate of aortic operations during the follow-up period, might potentially be explained by the young age of the patients and the more frequent family history of aortopathy or sudden cardiac death in this cohort.
The second important finding is a wide spectrum of rare genetic variants in our study cohort, suggesting a multigenic inheritance pattern of BAV-associated aortopathy. NOTCH1 variants were the most common genetic variants identified in our study ( Table 2 ). The impact of the NOTCH1 pathway in the pathogenesis of proximal aortic disease was reported in previous studies [12, 13] . Three NOTCH1 RGVs identified in our study were previously reported in thoracic aortic aneurysms in patients with a BAV [13] , as well as in patients with Adams-Oliver syndrome (i.e. ventricular septal defects, pulmonary atresia) [12] . Similarly, information on AXIN1 and NOS3 gene variants in combination with BAV disease were published previously [29, 30] . However, the genetic variants identified in our study were novel. Moreover, several novel RGVs were identified in the ELN, FN1, GATA5, PDIA2 and TGFBR1 genes. The FBN1 variant identified in our study was previously reported in combination with Marfan syndrome [14] . Finally, a nonsynonymous NKX2-5 alteration [i.e. c.355 G > T (p.A119S)] has been published previously in combination with congenital heart disease (i.e. atrioventricular septal defect and hypoplastic left heart syndrome) [15] .
Study limitations
Our study has some important limitations. Our mutational analysis included only 20 candidate genes, and unknown genetic defects may have remained undiscovered. A further extension of the aortopathy gene panel including MMP2, Tbx1, SMAD3, MATR3, SMAD2 and MMP14 would be reasonable. Implementation of whole-genome sequencing by the HiSeq approach would have enabled us potentially to associate additional genes with the BAV root phenotype and to expand the list of gene variants. Moreover, restricting the analysis to protein sequence-modifying mutations in protein-coding genes ignored the significance of regulatory mutations and non-coding genes. Furthermore, this preliminary study included only 63 of 124 (51%) patients with the BAV root phenotype, most of whom (i.e. 71%) were recruited retrospectively. A total of 17 of 124 (14%) patients died during the follow-up and were unavailable for genetic analysis. Ten of these patients died of potentially aortic-related causes and might have been those with the most severe genetic abnormalities. We were unable to test the families of the patients with the BAV root phenotype, to further evaluate the penetrance patterns of identified genetic defects, or substantiate the role of de novo RGVs in the cohort. Our patients had their primary operation over a 20-year period, and most of them were in their 60s or 70s at the time of their last follow-up. Their parents were not available for genetic analysis, and the data on siblings and children were insufficient. Moreover, we did not include a control group of patients with BAV without aortopathy; therefore, the prevalence of such genetic defects in other BAV subgroups remains unclear. Finally, the functional impact of genetic variants identified in our study remains to be clarified. Therefore, direct evidence of aortopathy induction by those rare variants is still lacking.
Despite these shortcomings, our findings demonstrate that rare genetic variants are common in the subgroup of patients with BAV who present with a root phenotype.
CONCLUSIONS
In summary, our preliminary study revealed a high prevalence of rare genetic variants in patients with a BAV root phenotype, indicative of the congenital origin of associated aortopathy in this specific BAV entity. A wide spectrum of genes implicated in the disorder has been identified, confirming a multigenic inheritance pattern of BAV disease.
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